A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide.
1/5 보강
[INTRODUCTION] Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS).
APA
Tanaka Y, Fujimura Y, et al. (2025). A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide.. IJU case reports, 8(5), 529-532. https://doi.org/10.1002/iju5.70085
MLA
Tanaka Y, et al.. "A Case of Drug-Induced Hypersensitivity Syndrome Caused by Apalutamide.." IJU case reports, vol. 8, no. 5, 2025, pp. 529-532.
PMID
40909306 ↗
Abstract 한글 요약
[INTRODUCTION] Apalutamide, an androgen receptor antagonist for prostate cancer, rarely causes drug-induced hypersensitivity syndrome (DIHS).
[CASE PRESENTATION] A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events.
[CONCLUSION] This report highlights the importance of caution and regular blood tests when using apalutamide owing to the risk of DIHS.
[CASE PRESENTATION] A 75-year-old male with prostate cancer and multiple bone metastases developed grade 2 rash and grade 3 liver dysfunction according to the Common Terminology Criteria for Adverse Events (CTCAE) 3 weeks after starting apalutamide with a GnRH antagonist, followed by a 3-day fever. Ten days later, symptoms worsened to grade 3 rash and grade 4 liver dysfunction. He met five diagnostic criteria for DIHS. Hormonal therapy was discontinued, and prednisolone plus intravenous immunoglobulin (IVIG) was administered. Fatigue resolved within 2 days, rash by day 6, and liver function improved to grade 2 by day 10. The patient is currently on abiraterone and a GnRH antagonist without adverse events.
[CONCLUSION] This report highlights the importance of caution and regular blood tests when using apalutamide owing to the risk of DIHS.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Oriental nose occidentalization and perinasal shaping by augmentation of the underdeveloped anterior nasal spine.
- The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer.
- [A Case of Pathological Complete Response Post‒Pembrolizumab Therapy for Recurrent Liver Metastasis of Ascending Colon Cancer].
- [Rectosigmoid Colon Cancer with Unresectable Liver Metastases That Responded Remarkably to Bevacizumab-Combined Chemotherapy-A Case Report].
- Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer.